BeOne Medicines Q2 revenue rises 30% to $1.7 billion; raises 2026 revenue guidance
BeOne Medicines reported second-quarter 2026 total revenue of $1.7 billion, up 30% from the prior year, and GAAP net income of $237 million, compared with $94 million a year earlier. The company raised its full-year 2026 total revenue guidance to $6.6 billion to $6.8 billion from $6.3 billion to $6.5 billion, which points to higher expected sales for shareholders.
Key points
- Q2 2026 total revenue $1.7 billion, up 30%; BRUKINSA global revenue $1.2 billion, up 31%
- GAAP diluted EPS per ADS $2.05 for Q2 2026, versus $0.84 in Q2 2025
- 2026 total revenue guidance raised to $6.6 billion to $6.8 billion; GAAP operating income guidance raised to $1.0 billion to $1.1 billion
- Q2 2026 free cash flow of $435 million, up 98% from $220 million
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.